drugset / Trial / NCT03137784

Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

NCT03137784

Phase 2/3 Completed 148 enrolled Novartis Pharmaceuticals
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug and 50 ug o.d. NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients

Timeline

Start
2017-05-04
Primary completion
2017-12-29
Completion
2017-12-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrrolate Small molecule 25 ug
Subject Glycopyrrolate Small molecule 50 ug

Indications